… There was no evidence of a difference in metatasis-free survival when enzalutamide and
abiraterone acetate were administered concurrently compared with abiraterone acetate alone (…

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease
with current standard-of-care therapies. Homologous recombination repair (HRR) gene …

… improvement in prostate-specific antigen … abiraterone acetate (with prednisone and androgen
deprivation therapy) represents the first androgen annihilation therapy for prostate cancer, …

… It can develop into castration-resistant prostate cancer (CRPC) … Abiraterone acetate is
an enzyme inhibitor of CPY17 that … -sensitive prostate cancer, both abiraterone acetate and …

… abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or
abiraterone acetate … orally once a day (in the abiraterone and enzalutamide trial). Patients were …

… from donors not receiving any form of prostate cancer treatment (n = 8) were transferred
to BHI media supplemented with 100 μg/mL of abiraterone acetate (AA) or vehicle (EtOH). …

… Whether we are referring to prioritize the use of abiraterone acetate plus prednisone or
enzalutamide, it is obvious that both treatments are worth having within the prostate cancer …

… PEACE-1 is a phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone
(abiraterone) and/or local radiotherapy. First results show that adding abiraterone to ADT+…

… to novel hormonal therapy in prostate cancer. Abiraterone acetate and prednisone (AAP) is
… treatment for men with metastatic castration-sensitive prostate cancer (mCSPC) based on the …

… antagonist, and abiraterone acetate, a specific … to as abiraterone) [1,2,3,4,5,6,7,8]. The
PREVAIL trial of chemotherapy-naive patients with metastatic castration-resistant prostate cancer (…